Brisbane – AIBN Seminar – Professor Mark A. F. Kendall, AIBN Group Leader

AIBN SEMINAR SERIES:

Presenter:

Professor Mark A. F. Kendall, AIBN Group Leader
Title:

Improving the reach of vaccines to the developing world with Nanopatches
Time:

12:00pm
Venue:

Parnell Building 07, Lecture Room 222

Date: Thursday 14 March 2013

Improving the reach of vaccines to the developing world with Nanopatches

Vaccines have produced one of the largest increases in the age of life expectancy in human history. However massive challenges remain, with 17 million deaths per year due to infectious disease – mostly in the developing-world.

I will discuss the particular challenges holding back vaccines within the developing world; together with potential solutions under development.

My particular focus will move to the needle and syringe: currently the main vaccination method, which was first invented in 1853. The needle is holding back the rollout of vaccines by (1) placing vaccine into muscle, arguably missing our immune “sweet spot”); (2) the need for maintaining the refrigeration “cold chain” of the vaccine in liquid form; and (3) cross-contamination through needle-stick injuries.

I will then introduce the Nanopatch – conceived to tackle all three of these needle-based problems – and outline the Nanopatch journey from idea towards clinical utility as a medical device product.

Professor Mark A.F. Kendall has more than 15 years of experience researching the field of needle-free gene and drug delivery to skin with micro-nanostructures, authoring over 334 refereed journal, conference papers, and presentations, including invited Keynote and Plenary lectures in more than twenty countries, as well as served as Session Moderators. In addition, Mark has been an inventor on more than 96 patents (with 4 more patent applications in process) and has worked closely with Industrial partners in the technology transfer from concept to commercialisation. His Biolistics technology has been successfully commercialised with PowderMed (the technology transfer company) purchased by Pfizer for $400 M in 2006.

Mark joined the University of Queensland for a Professorial position after 8 years at the University of Oxford, where he was Associate Director of the PowderJect Centre for Gene and Drug Delivery Research, a University Research Lecturer and College Lecturer (MagdalenCollege). He was one of the youngest lecturers at Oxford. He is Co-Founder of Vaxxas, a spin out company with $15 M of investment consortium funding to commercialize the Nanopatch. In addition to research at UQ, Mark lectures undergraduate students in biomedical fluid mechanics. Most recently, Mark was made a Rolex Laureate.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s